---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-000420"
form_type: "8-K"
ticker: "SNOA"
cik: "0001367083"
company_name: "Sonoma Pharmaceuticals, Inc."
filed_at: "2023-01-31T23:59:59+00:00"
generated_at: "2026-06-20T05:10:55.262473+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sonoma enters exclusive South Korea distribution deal with Daewoong for Primocyn

## Summary
- Exclusive distribution agreement effective Jan 26, 2023 for Primocyn Skin Solution (Microcyn technology) in South Korea.
- Initial term of two years, automatically renewing for two-year periods unless terminated.
- Daewoong responsible for obtaining marketing authorization and all regulatory clearances in the territory.
- Minimum purchase thresholds (redacted) required to maintain exclusivity beyond second year; initial fee also redacted.
- Sonoma to provide registration dossier within 90 days; Daewoong to apply for marketing authorization.

## SEC filing metadata
- accession: 0001683168-23-000420
- form_type: 8-K
- ticker: SNOA
- cik: 0001367083
- company_name: Sonoma Pharmaceuticals, Inc.
- filed_at: 2023-01-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367083/000168316823000420/0001683168-23-000420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367083/000168316823000420/sonoma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-000420
- JSON: https://secwatch.observer/filing/0001683168-23-000420.json
- Plain text: https://secwatch.observer/filing/0001683168-23-000420.txt

## Key facts
- Material Agreements
  Sonoma Pharmaceuticals, Inc. entered into Exclusive Distribution Agreement with Daewoong Pharmaceutical Co., Ltd. valued at Exclusive distribution agreement for Primocyn Skin Solution products containing Microcyn technology (effective 2023-01-26).
  - Action: entry
  - Agreement: license
  - Counterparty: Daewoong Pharmaceutical Co., Ltd.
  - Value: Exclusive distribution agreement for Primocyn Skin Solution products containing Microcyn technology
  - Effective: 2023-01-26
  source text: Effective January 26, 2023, we entered into an exclusive distribution agreement with Daewoong Pharmaceutical Co., Ltd. for the marketing and distribution of Primocyn TM Skin Solution products, containing our Microcyn® technology, in South Korea.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367083/000168316823000420/0001683168-23-000420-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.